Summer is peak season for barefoot activities, making it the time of year when plantar warts are most commonly spread.
They develop when the human papilloma virus (HPV) enters a cut or break in the skin, causing an infection. Approximately 10% of the population experiences having plantar warts, which can spread, cause pain and be hard to treat.
Swift’s Summer Feet campaign supports the wart awareness efforts by addressing patients suffering from stubborn foot lesions. It aims to educate practitioners and the public on the benefits of hyperthermic therapy — a non-invasive, clinically-proven wart treatment that outperforms traditional approaches like acids or freezing.
Recently granted FDA 510(k) clearance for expanded indications in treating common and plantar warts, the SwiftPro™ device delivers a precise, highly controlled dose of microwave energy to target infected cells. Unlike traditional methods that can cause tissue damage and discomfort, this unique hyperthermic therapy activates the immune system to clear skin condition, and the underlying HPV naturally. This results in significantly better outcomes with Swift clinically proven to be 85% effective in clearing warts and verrucae.
“Wart Awareness Month is an opportunity to change the conversation and approach around how common and plantar warts are treated,” said Ian Stevens, Chief Executive Officer at Emblation. “Our summer awareness campaign focuses on educating practitioners and patients about this breakthrough microwave technology. SwiftPro is elevating the standard of care for wart patients, boasting an 85% efficacy rate and near-zero recurrence.”™
Emblation recently announced the availability of the Swiftscope™ app that works in tandem with its SwiftPro™ device. The app allows clinicians to capture consistent images, track and compare treatment progress side-by-side, and confidently guide patients through their treatment. The app is available for smartphone and tablet devices, and works with dermatoscopes, enabling premium visualization and documentation. Through a recent strategic partnership with DermLite, the DL-1 dermatoscope is now available directly through the Swift Store. This gives podiatrists immediate access to advanced diagnostic tools that enhance both clinical decision-making and patient education.
SwiftPro™ and the Swiftscope app™ are available in many global markets, including the U.S., U.K., and Canada. For more information visit swiftbyemblation.com.
About Emblation
Based in Stirling, Scotland with U.S. headquarters in Lincoln, R.I., Emblation launched Swiftâ in 2016. Since then, over 700,000 treatments have been conducted globally with over 85% of wart and verrucae patients experiencing complete resolution and a low recurrence rate compared to traditional methods. The company recently received FDA 510(k) clearance for expanded indications of its Swift and SwiftProâ Systems for the treatment of common and plantar warts.
Media Contact: Emblation
844-793-8776 media@emblation.com
